Status Epilepticus - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Status Epilepticus - Pipeline Review, H2 2016

Status Epilepticus - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Status Epilepticus - Pipeline Review, H2 2016
Published Jul 20, 2016
65 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Status Epilepticus - Pipeline Review, H2 2016, provides an overview of the Status Epilepticus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Status Epilepticus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Status Epilepticus and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Status Epilepticus
- The report reviews pipeline therapeutics for Status Epilepticus by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Status Epilepticus therapeutics and enlists all their major and minor projects
- The report assesses Status Epilepticus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Status Epilepticus

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Status Epilepticus
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Status Epilepticus pipeline depth and focus of In

  
Source:
Document ID
GMDHC8261IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Status Epilepticus Overview71
Therapeutics Development82
  Pipeline Products for Status Epilepticus Overview81
  Pipeline Products for Status Epilepticus Comparative Analysis91
Status Epilepticus Therapeutics under Development by Companies101
Status Epilepticus Therapeutics under Investigation by Universities/Institutes111
Status Epilepticus Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Status Epilepticus Products under Development by Companies151
Status Epilepticus Products under Investigation by Universities/Institutes161
Status Epilepticus Companies Involved in Therapeutics Development173
  Marinus Pharmaceuticals, Inc.171
  Sage Therapeutics, Inc.181
  Shire Plc191
Status Epilepticus Therapeutics Assessment209
  Assessment by Monotherapy Products201
  Assessment by Target212
  Assessment by Mechanism of Action232
  Assessment by Route of Administration252
  Assessment by Molecule Type272
Drug Profiles2921
  AMPX-0079 Drug Profile291
  fosphenytoin sodium Drug Profile301
  ganaxolone Drug Profile315
  LSPGR-1 Drug Profile361
  midazolam hydrochloride Drug Profile371
  SAGE-217 Drug Profile382
  SAGE-689 Drug Profile401
  sepranolone Drug Profile417
  Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus Drug Profile481
  TG-4155 Drug Profile491
Status Epilepticus Dormant Projects501
Status Epilepticus Product Development Milestones5113
  Featured News &Press Releases511
    Jun 22, 2016: Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV511
    Jun 13, 2016: Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures511
    Apr 19, 2016: Marinus Pharmaceuticals Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus521
    Apr 17, 2016: Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting532
    Apr 15, 2016: Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus551
    Apr 12, 2016: Marinus Pharmaceuticals to Present Ganaxolone IV Data at American Academy of Neurology Annual Meeting551
    Mar 03, 2016: Sage Therapeutics to Present SAGE-547 Clinical Data and SRSE Health Economic Data in Five Abstracts at the American Academy of Neurology 2016 Annual Meeting561
    Dec 15, 2015: SAGE Updates Guidance for Top-Line Results of Phase 3 STATUS Trial of SAGE-547561
    Dec 02, 2015: SAGE to Present Poster Presentations on SAGE-547 at the American Epilepsy Society 69th Annual Meeting571
    Aug 17, 2015: SAGE Announces First Patient Treated in Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus581
    Aug 06, 2015: SAGE Receives Special Protocol Assessment for Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus581
    Jun 09, 2015: SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of SAGE-547 in Postpartum Depression591
    May 14, 2015: SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus602
    Apr 22, 2015: Ligand Earns Milestone from SAGE Therapeutics for SAGE-547621
    Apr 20, 2015: SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol to Evaluate SAGE-547 in Patients With Super-Refractory Status Epilepticus631
Appendix642
  Methodology641
  Coverage641
  Secondary Research641
  Primary Research641
  Expert Panel Validation641
  Contact Us641
  Disclaimer651

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Status Epilepticus - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Status-Epilepticus-Pipeline-Review-H2-2016-2088-16235>
  
APA:
Global Markets Direct - Market Research. (2016). Status Epilepticus - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Status-Epilepticus-Pipeline-Review-H2-2016-2088-16235>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.